LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal.
Faculdade de Medicina, Universidade do Porto, Portugal.
Nanomedicine (Lond). 2020 Feb;15(3):259-271. doi: 10.2217/nnm-2019-0256. Epub 2019 Dec 2.
Design nanostructured lipid carriers (NLC) to facilitate drug delivery to tuberculosis-infected areas, exploiting macrophage mannose receptors and assess their uptake in a 3D human lung model. NLCs and mannosylated-NLCs were synthetized and characterized. Their uptake and biocompatibility were tested in a 3D human lung model. The formulations have appropriate size (170-202 nm) and morphology for lung deposition. Cell membrane integrity was maintained and no significant pro-inflammatory cytokine (IL-1β, IL-8 and TNF-α) secretion or morphological changes were observed 24 h post nanoparticles exposure. NLCs and mannosylated NLCs were distributed in the apical side of the lung tissue, both in macrophages and in epithelial cells. NLCs are biocompatible carriers and can be used for pulmonary drug delivery.
设计纳米结构脂质载体（NLC）以利用巨噬细胞甘露糖受体将药物递送至结核感染区域，并评估它们在 3D 人肺模型中的摄取情况。合成并表征了 NLC 和甘露糖基化-NLC。在 3D 人肺模型中测试了它们的摄取和生物相容性。这些制剂具有适合肺部沉积的适当粒径（170-202nm）和形态。细胞膜完整性得以维持，在纳米颗粒暴露后 24 小时内未观察到明显的促炎细胞因子（IL-1β、IL-8 和 TNF-α）分泌或形态变化。NLC 和甘露糖基化 NLC 分布在肺组织的顶部，既在巨噬细胞中，也在上皮细胞中。NLC 是生物相容性载体，可用于肺部药物递送。
